- You are here: Home > Bioinformatics Analyst Position – DNAseq Analysis
You are here
Bioinformatics Analyst Position – DNAseq Analysis
Bioinformatics Analyst Position – DNAseq Analysis
The Centro Nacional de Análisis Genómico (CNAG-CRG) is one of the largest Genome Sequencing Centers in Europe. CNAG-CRG researchers participate in major International Genomic Initiatives such as the International Cancer Genome Consortium (ICGC), the International Human Epigenome Consortium (IHEC), the International Rare Diseases Research Consortium (IRDiRC), the Human Cell Atlas (HCA), the European Infrastructure for life-science information (ELIXIR), as well as in several EU-funded projects. The CNAG-CRG aims to carry out large-scale projects in DNA/RNA sequence analysis for the improvement of quality of life in collaboration with the Spanish, European and International Research Community. The CNAG-CRG operates 6 Illumina and 4 Oxford Nanopore sequencing instruments together with an outstanding computing infrastructure (7.6 petabyte of data storage and 3472 cores of computing). The operation is certified ISO 9001 and accredited ISO 17025 and serves to deliver standardized, high quality data for research and clinics. Single-cell genomics and long-read sequencing are strategic priorities for CNAG-CRG.
CNAG-CRG is integrated with the Centre for Genomic Regulation (CRG), an international biomedical research institute of excellence, based in Barcelona, Spain, with more than 400 scientists from 44 countries. The CRG shares principles of an interdisciplinary, motivated and creative scientific team that is supported by high-end and innovative technologies and a flexible and efficient administration. CRG has been conferred with a badge of ‘HR Excellence in Research’ by the European Commission, in recognition to its progress in implementing the European Charter for Researchers and the Code of Conduct for Recruitment of Researchers, that among others consists of transparent, merit-based recruitment procedures and attractive work-life balance working conditions.
We have an opening for a Bioinformatics Analyst through the EU-funded project Beyond 1 Million Genomes (B1MG). The B1MG project aims to make significant in ways into the standardization of genome sequencing applied to personalized medicine and data sharing. Topics for the Bioinformatics Analyst include analysis of the analysis of DNA sequencing experiments (next-generation sequencing), the development of measures to evaluate results and interpretation. We are looking for highly motivated and creative thinking individuals who are interested in working in an environment with high the technical sophistication.
About the team
The successful candidates will be integrated into the B1MG project of the Biomedical Genomics Group lead by Dr. Ivo Gut.
Dr. Ivo Gut is the CNAG-CRG director and head of the Biomedical Genomics group. He coordinates the BCLL@las project and the European Advanced Sequencing Infrastructure project (EASI-Genomics), funded by the European Commission. Dr. Ivo Gut participates in H2020 projects B-CAST, SPIDIA-4P, ELIXIR-ACCELERATE, SOLVE-RD, EJP-RD and EuCanCan. In addition, the CNAG-CRG participates in major Spanish initiatives in Personalized Medicine such as the PERIS projects MedPERCAN and URDCat, the 1,000 Catalan Genomes project, and the Navarra project on personalized medicine. The Biomedical Genomics Group focusses on furthering the understanding of diseases using different types of genomic data, novel statistical approaches and bioinformatics. Big data approaches are used to identify patterns on genome, transcriptome and epigenome level that correlate with a disease and the evolution across the course of the disease. The objective is to answer questions that go beyond the initial hypotheses that underlay the studies to shed light on how genome sequence, structure and usage relates to disease, disease initiation, disease progression and disease mechanisms. The group also studies genomic features related to disease at different cellular levels. The disease areas range from rare to common disorders including cancer.
Whom would we like to hire?
- You have good knowledge of analyzing next-generation sequencing data
- You have experience working with remote distributed job systems (e.g Slurm)
Desirable but not required
- You hold a PhD degree
Education and training
- You hold aMasters degree in Bioinformatics, Mathematics, Statistics or similar
- You are fluent in English
- You are competent in R or Python
- You are very well organized
- You are good at communicating with other scientists
The Offer – Working Conditions
- Contract duration: 2 years
- Estimated annual gross salary: Salary is commensurate with qualifications and consistent with our pay scales.
- Target start date: 1st September 2020
We provide a highly stimulating environment with state-of-the-art infrastructures, and unique professional career development opportunities.
We offer and promote a diverse and inclusive environment and welcomes applicants regardless of age, disability, gender, nationality, race, religion or sexual orientation.
We are committed to reconcile a work and family life for our employees and are offering the opportunity to benefit from annual leave, flexible working hours and teleworking.
All applications must include:
- A motivation letter addressed to Dr. Ivo Gut.
- A complete CV including contact details.
- Contact details of two referees.
All applications must be addressed to Dr. Ivo Gut and be submitted online through the "Apply" button below.
- Pre-selection: The pre-selection process will be based on qualifications and expertise reflected on the candidates CVS. It will be merit-based.
- Interview: Preselected candidates will be interviewed by the Hiring Manager and Graduate Committe
- Offer Letter: Once the successful candidate is identified the Human Resources department will send a Job Offer, specifying the start day, salary, working conditions, among other important details.
Deadline: Please submit your application by 15th of July 2020.
This project has received fundig from the European Union's Horizon 2020 research and innovation programme under grant agreement No 951724.